GRAIL LLC is a biotechnology company. It focuses on developing technologies for early cancer detection. GRAIL LLC is based in Menlo Park, United States.
| Revenue (Most Recent Fiscal Year) | $147.17M |
| Net Income (Most Recent Fiscal Year) | $-408.35M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 21.71 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.41 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -320.38% |
| Net Margin (Trailing 12 Months) | -236.95% |
| Return on Equity (Trailing 12 Months) | -15.88% |
| Return on Assets (Trailing 12 Months) | -14.02% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.95 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.95 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $56.93 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.56 |
| Earnings per Share (Most Recent Fiscal Year) | $-11.11 |
| Diluted Earnings per Share (Trailing 12 Months) | $-9.75 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 44.67M |
| Free Float | 43.85M |
| Market Capitalization | $3.59B |
| Average Volume (Last 20 Days) | 0.71M |
| Beta (Past 60 Months) | 3.25 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.83% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |